<p>隨着全球市場調整美聯儲最近的降息和混合經濟信號，小型股表現出韌性，特別是在美國，羅素 2000 指數的表現優於大型同行。在這個動態環境中，識別亞洲有前景的股票需要敏鋭的眼光，尋找能夠應對貨幣政策變化並利用區域增長機會的公司。</p>
<h3>亞洲十大未被發現的基本面強勁的寶藏股</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dear LifeLtd</td>
<td>53.23%</td>
<td>18.86%</td>
<td>15.70%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Central Forest Group</td>
<td>NA</td>
<td>5.20%</td>
<td>24.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kanda HoldingsLtd</td>
<td>23.54%</td>
<td>3.84%</td>
<td>10.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nice</td>
<td>78.50%</td>
<td>1.97%</td>
<td>13.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>安徽華仁健康藥業</td>
<td>55.17%</td>
<td>17.65%</td>
<td>10.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>華思控股</td>
<td>6.89%</td>
<td>4.80%</td>
<td>41.72%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>泰信電氣</td>
<td>37.42%</td>
<td>10.92%</td>
<td>7.66%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>江西江南新材料科技</td>
<td>68.65%</td>
<td>15.68%</td>
<td>14.93%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>四川自貢輸送機械集團</td>
<td>54.32%</td>
<td>21.85%</td>
<td>16.70%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>浙江博發電氣</td>
<td>39.35%</td>
<td>-1.41%</td>
<td>-47.96%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們亞洲未被發現的基本面強勁的寶藏股篩選器中的 2502 只股票的完整列表。</p>
<p>在這裏，我們重點介紹了我們獨家的篩選器中的幾隻最愛。</p>
<h2>蘇美達 (SHSE:600710)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 蘇美達有限公司在中國從事供應和工業鏈業務，市值為 140.6 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過其在中國的供應和工業鏈業務產生收入，市值為 140.6 億人民幣。</p>
<p>蘇美達過去一年的盈利增長為 9.8%，超過了貿易分銷行業的-12.9% 的變化，突顯了其在挑戰性行業中的強勁表現。該公司報告 2025 年前九個月的淨收入為 11.0369 億人民幣，較去年 1,003.08 億人民幣有所增長。以顯著折扣交易——比估計的公允價值低 67.1%——蘇美達似乎相較於同行和行業標準被低估。值得注意的是，其負債權益比在五年內從 81.3% 顯著改善至僅 22.6%，這表明其財務管理有效，未來增長潛力巨大。</p>
<ul>
<li>點擊這裏深入瞭解蘇美達的完整分析健康報告。</li>
<li>通過查看我們的歷史業績報告，獲取蘇美達的歷史表現見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/07b615c2-7d96-4be8-a874-c65441485e46/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/07b615c2-7d96-4be8-a874-c65441485e46/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:600710 截至 2025 年 12 月的盈利和收入增長</p>
<h2>天水中興生物科技有限公司 (SZSE:002772)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 天水中興生物科技有限公司從事食用真菌的研究、開發、生產和銷售，業務覆蓋中國及國際市場，市值約為 53.6 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要從農業種植行業產生收入，報告收入約為 19.9 億人民幣。</p>
<p>天水中興生物科技在生物科技領域是一家有前景的參與者，過去一年其盈利增長達到 235%，超過了食品行業 4.8% 的整體增長。該公司 2025 年前九個月的淨收入達到 2.04 億人民幣，顯著高於去年 8900 萬人民幣。以 22 倍的市盈率相比中國市場平均 42.9 倍仍具吸引力。其債務管理值得稱讚，負債權益比在五年內從 91.8% 降至 74.1%，利息覆蓋率接近十六倍 EBIT。</p>
<ul>
<li>點擊探索我們在天水中興生物科技有限公司健康報告中的詳細發現。</li>
<li>查看我們的歷史業績報告，以獲取天水中興生物科技有限公司的過去表現見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef43b2da-3d5d-4230-bd91-b8c4dfd6ff19/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef43b2da-3d5d-4230-bd91-b8c4dfd6ff19/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002772 截至 2025 年 12 月的負債權益比</p>
<h2>久光製藥 (TSE:4530)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 久光製藥株式會社專注於在日本製造和銷售藥品，市值為 3046.3 億日元。</p>
<p><strong>運營：</strong> 該公司主要通過在日本銷售藥品產生收入。其財務表現受生產成本和市場需求等因素的影響。市值為 3046.3 億日元，反映了其在行業中的地位。</p>
<p>在製藥行業具有顯著影響力的久光製藥，過去一年顯示出 34% 的強勁盈利增長，超過行業平均 9.6%。以顯著折扣交易，低於其估計公允價值的 53.5%。該公司財務狀況良好，現金超過總債務，且自由現金流為正。最近的戰略舉措包括完成價值 122.7 億日元的股票回購計劃，提升了股東價值。此外，他們將股息從每股 43 日元提高至 45 日元，反映了對其財務健康和未來前景的信心。</p>
<ul>
<li>點擊這裏發現久光製藥的細微差別，查看我們的詳細分析健康報告。</li>
<li>通過我們的歷史報告獲取久光製藥的過去趨勢和表現見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/90b7772f-ce8e-4189-b4aa-a39aa3f899dc/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/90b7772f-ce8e-4189-b4aa-a39aa3f899dc/chart/earnings-and-revenue-growth"/></p>
<p>TSE:4530 截至 2025 年 12 月的盈利和收入增長</p>
<h2>接下來該如何？</h2>
<ul>
<li>在這裏深入瞭解我們完整的 2502 個具有強大基本面的亞洲未被發現的寶藏。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>使用 Simply Wall St 提升您的投資組合，這是尋求全球市場覆蓋的投資者的終極應用程序。</li>
</ul>
<h2>考慮其他策略？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成購買或出售任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>移動基礎設施用於國防和災害</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

蘇美達

<p>這篇文章強調了在全球市場調整中，亞洲有前景的小型股票。它列出了 10 家基本面強勁的公司，包括蘇美達、天水中興生物科技和久光製藥。蘇美達顯示出強勁的盈利增長和改善的債務管理。天水中興生物科技具有顯著的盈利增長和吸引人的估值。久光製藥展現出強勁的盈利增長、良好的財務健康和股東價值提升。文章鼓勵探索完整的 2502 只股票名單，並使用 Simply Wall St 獲取投資見解</p>

<p>As global markets adjust to the Federal Reserve's recent interest rate cut and mixed economic signals, small-cap stocks have shown resilience, particularly in the U.S., with the Russell 2000 Index outperforming its larger peers. In this dynamic environment, identifying promising stocks in Asia requires a keen eye for companies that can navigate shifting monetary policies and capitalize on regional growth opportunities.</p>
<div class="lb-trans"><p>隨着全球市場調整美聯儲最近的降息和混合經濟信號，小型股表現出韌性，特別是在美國，羅素 2000 指數的表現優於大型同行。在這個動態環境中，識別亞洲有前景的股票需要敏鋭的眼光，尋找能夠應對貨幣政策變化並利用區域增長機會的公司。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals In Asia</h3>
<div class="lb-trans"><h3>亞洲十大未被發現的基本面強勁的寶藏股</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dear LifeLtd</td>
<td>53.23%</td>
<td>18.86%</td>
<td>15.70%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Central Forest Group</td>
<td>NA</td>
<td>5.20%</td>
<td>24.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kanda HoldingsLtd</td>
<td>23.54%</td>
<td>3.84%</td>
<td>10.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nice</td>
<td>78.50%</td>
<td>1.97%</td>
<td>13.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Anhui Huaren Health Pharmaceutical</td>
<td>55.17%</td>
<td>17.65%</td>
<td>10.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Huasi Holding</td>
<td>6.89%</td>
<td>4.80%</td>
<td>41.72%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Tai Sin Electric</td>
<td>37.42%</td>
<td>10.92%</td>
<td>7.66%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Jiangxi Jiangnan New Material Technology</td>
<td>68.65%</td>
<td>15.68%</td>
<td>14.93%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Sichuan Zigong Conveying Machine Group</td>
<td>54.32%</td>
<td>21.85%</td>
<td>16.70%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Zhejiang Bofay Electric</td>
<td>39.35%</td>
<td>-1.41%</td>
<td>-47.96%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dear LifeLtd</td>
<td>53.23%</td>
<td>18.86%</td>
<td>15.70%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Central Forest Group</td>
<td>NA</td>
<td>5.20%</td>
<td>24.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kanda HoldingsLtd</td>
<td>23.54%</td>
<td>3.84%</td>
<td>10.38%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Nice</td>
<td>78.50%</td>
<td>1.97%</td>
<td>13.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>安徽華仁健康藥業</td>
<td>55.17%</td>
<td>17.65%</td>
<td>10.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>華思控股</td>
<td>6.89%</td>
<td>4.80%</td>
<td>41.72%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>泰信電氣</td>
<td>37.42%</td>
<td>10.92%</td>
<td>7.66%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>江西江南新材料科技</td>
<td>68.65%</td>
<td>15.68%</td>
<td>14.93%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>四川自貢輸送機械集團</td>
<td>54.32%</td>
<td>21.85%</td>
<td>16.70%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>浙江博發電氣</td>
<td>39.35%</td>
<td>-1.41%</td>
<td>-47.96%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 2502 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們亞洲未被發現的基本面強勁的寶藏股篩選器中的 2502 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>在這裏，我們重點介紹了我們獨家的篩選器中的幾隻最愛。</p>
</div><h2>Sumec (SHSE:600710)</h2>
<div class="lb-trans"><h2>蘇美達 (SHSE:600710)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Sumec Corporation Limited operates in the supply and industrial chain business in China, with a market cap of CN¥14.06 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 蘇美達有限公司在中國從事供應和工業鏈業務，市值為 140.6 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates its revenue primarily through its supply and industrial chain operations in China. It has a market capitalization of CN¥14.06 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其在中國的供應和工業鏈業務產生收入，市值為 140.6 億人民幣。</p>
</div><p>Sumec's earnings growth of 9.8% over the past year outpaced the Trade Distributors industry, which saw a -12.9% change, highlighting its robust performance in a challenging sector. The company reported net income of CNY 1,103.69 million for the first nine months of 2025, up from CNY 1,003.08 million last year. Trading at a significant discount—67.1% below estimated fair value—Sumec seems undervalued compared to peers and industry standards. Notably, its debt-to-equity ratio has improved dramatically from 81.3% to just 22.6% over five years, suggesting effective financial management and potential for future growth.</p>
<div class="lb-trans"><p>蘇美達過去一年的盈利增長為 9.8%，超過了貿易分銷行業的-12.9% 的變化，突顯了其在挑戰性行業中的強勁表現。該公司報告 2025 年前九個月的淨收入為 11.0369 億人民幣，較去年 1,003.08 億人民幣有所增長。以顯著折扣交易——比估計的公允價值低 67.1%——蘇美達似乎相較於同行和行業標準被低估。值得注意的是，其負債權益比在五年內從 81.3% 顯著改善至僅 22.6%，這表明其財務管理有效，未來增長潛力巨大。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Sumec.</li>
<li>Gain insights into Sumec's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解蘇美達的完整分析健康報告。</li>
<li>通過查看我們的歷史業績報告，獲取蘇美達的歷史表現見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/07b615c2-7d96-4be8-a874-c65441485e46/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/07b615c2-7d96-4be8-a874-c65441485e46/chart/earnings-and-revenue-growth"/></p>
<p>SHSE:600710 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>SHSE:600710 截至 2025 年 12 月的盈利和收入增長</p>
</div><h2>Tianshui Zhongxing Bio-technologyLtd (SZSE:002772)</h2>
<div class="lb-trans"><h2>天水中興生物科技有限公司 (SZSE:002772)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Tianshui Zhongxing Bio-technology Co., Ltd. is involved in the research, development, production, and sale of edible fungi both in China and internationally, with a market capitalization of approximately CN¥5.36 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 天水中興生物科技有限公司從事食用真菌的研究、開發、生產和銷售，業務覆蓋中國及國際市場，市值約為 53.6 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates its revenue primarily from the agricultural planting industry, with reported revenues of approximately CN¥1.99 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要從農業種植行業產生收入，報告收入約為 19.9 億人民幣。</p>
</div><p>Tianshui Zhongxing Bio-technology, a promising player in the biotech sector, has seen its earnings soar by 235% over the past year, outpacing the broader food industry growth of 4.8%. The company's net income for the first nine months of 2025 reached CNY 204 million, significantly up from CNY 89 million a year prior. With a price-to-earnings ratio of 22x, it remains attractively valued compared to China's market average of 42.9x. Its debt management is commendable with a reduced debt to equity ratio from 91.8% to 74.1% over five years and an interest coverage of nearly sixteen times EBIT.</p>
<div class="lb-trans"><p>天水中興生物科技在生物科技領域是一家有前景的參與者，過去一年其盈利增長達到 235%，超過了食品行業 4.8% 的整體增長。該公司 2025 年前九個月的淨收入達到 2.04 億人民幣，顯著高於去年 8900 萬人民幣。以 22 倍的市盈率相比中國市場平均 42.9 倍仍具吸引力。其債務管理值得稱讚，負債權益比在五年內從 91.8% 降至 74.1%，利息覆蓋率接近十六倍 EBIT。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Tianshui Zhongxing Bio-technologyLtd's health report.</li>
<li>Review our historical performance report to gain insights into Tianshui Zhongxing Bio-technologyLtd's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在天水中興生物科技有限公司健康報告中的詳細發現。</li>
<li>查看我們的歷史業績報告，以獲取天水中興生物科技有限公司的過去表現見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ef43b2da-3d5d-4230-bd91-b8c4dfd6ff19/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/ef43b2da-3d5d-4230-bd91-b8c4dfd6ff19/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002772 Debt to Equity as at Dec 2025</p>
<div class="lb-trans"><p>SZSE:002772 截至 2025 年 12 月的負債權益比</p>
</div><h2>Hisamitsu Pharmaceutical (TSE:4530)</h2>
<div class="lb-trans"><h2>久光製藥 (TSE:4530)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Hisamitsu Pharmaceutical Co., Inc. focuses on the manufacturing and sale of pharmaceuticals in Japan, with a market cap of ¥304.63 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 久光製藥株式會社專注於在日本製造和銷售藥品，市值為 3046.3 億日元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from the sale of pharmaceuticals in Japan. Its financial performance is influenced by factors such as production costs and market demand for its products. The market cap stands at ¥304.63 billion, reflecting its position within the industry.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過在日本銷售藥品產生收入。其財務表現受生產成本和市場需求等因素的影響。市值為 3046.3 億日元，反映了其在行業中的地位。</p>
</div><p>With a notable presence in the pharmaceutical sector, Hisamitsu Pharmaceutical has shown robust earnings growth of 34% over the past year, outpacing the industry average of 9.6%. Trading at a significant discount, it stands 53.5% below its estimated fair value. The company is financially sound with more cash than total debt and positive free cash flow. Recent strategic moves include completing a share buyback program worth ¥12.27 billion, enhancing shareholder value. Furthermore, they have increased dividends to ¥45 per share from ¥43 previously, reflecting confidence in their financial health and future prospects.</p>
<div class="lb-trans"><p>在製藥行業具有顯著影響力的久光製藥，過去一年顯示出 34% 的強勁盈利增長，超過行業平均 9.6%。以顯著折扣交易，低於其估計公允價值的 53.5%。該公司財務狀況良好，現金超過總債務，且自由現金流為正。最近的戰略舉措包括完成價值 122.7 億日元的股票回購計劃，提升了股東價值。此外，他們將股息從每股 43 日元提高至 45 日元，反映了對其財務健康和未來前景的信心。</p>
</div><ul>
<li>Click here to discover the nuances of Hisamitsu Pharmaceutical with our detailed analytical health report.</li>
<li>Gain insights into Hisamitsu Pharmaceutical's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現久光製藥的細微差別，查看我們的詳細分析健康報告。</li>
<li>通過我們的歷史報告獲取久光製藥的過去趨勢和表現見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/90b7772f-ce8e-4189-b4aa-a39aa3f899dc/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/90b7772f-ce8e-4189-b4aa-a39aa3f899dc/chart/earnings-and-revenue-growth"/></p>
<p>TSE:4530 Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>TSE:4530 截至 2025 年 12 月的盈利和收入增長</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下來該如何？</h2>
</div><ul>
<li>Delve into our full catalog of 2502 Asian Undiscovered Gems With Strong Fundamentals here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解我們完整的 2502 個具有強大基本面的亞洲未被發現的寶藏。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>使用 Simply Wall St 提升您的投資組合，這是尋求全球市場覆蓋的投資者的終極應用程序。</li>
</ul>
</div><h2>Contemplating Other Strategies?</h2>
<div class="lb-trans"><h2>考慮其他策略？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成購買或出售任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移動基礎設施用於國防和災害</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

亞洲未被發現的寶藏：2025 年 12 月的潛力股